U.S. flag

An official website of the United States government

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 20 books (56 items)

  • Quoted phrase not found.
  • See the search details.
1.
Bimekizumab (Bimzelx): CADTH Reimbursement Recommendation: Indication: The treatment of adult patients with active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy [Internet].

Bimekizumab (Bimzelx): CADTH Reimbursement Recommendation: Indication: The treatment of adult patients with active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2024 Jun.

Table of Contents

2.
Guselkumab (Tremfya): CADTH Reimbursement Recommendation: Indication: For the treatment of adult patients with active psoriatic arthritis. Guselkumab can be used alone or in combination with a conventional disease modifying antirheumatic drug (e.g., methotrexate) [Internet].

Guselkumab (Tremfya): CADTH Reimbursement Recommendation: Indication: For the treatment of adult patients with active psoriatic arthritis. Guselkumab can be used alone or in combination with a conventional disease modifying antirheumatic drug (e.g., methotrexate) [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Dec.

Table of Contents

3.
PDQ Cancer Information Summaries [Internet].

PDQ Cancer Information Summaries [Internet].

Bethesda (MD): National Cancer Institute (US); 2002-.

Table of Contents

4.
Ruxolitinib (Jakavi): CADTH Reimbursement Recommendation: Indication: For the treatment of steroid refractory or dependent acute graft-versus-host disease in patients aged 12 years and older [Internet].

Ruxolitinib (Jakavi): CADTH Reimbursement Recommendation: Indication: For the treatment of steroid refractory or dependent acute graft-versus-host disease in patients aged 12 years and older [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Oct.

Table of Contents

5.
Bimekizumab (Bimzelx): CADTH Reimbursement Recommendation: Indication: For the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy [Internet].

Bimekizumab (Bimzelx): CADTH Reimbursement Recommendation: Indication: For the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Apr.

Table of Contents

6.
Bimekizumab (Bimzelx): CADTH Reimbursement Recommendation: Indication: For the treatment of adult patients with active psoriatic arthritis. Bimekizumab can be used alone or in combination with a conventional non-biologic disease-modifying antirheumatic drug (e.g., methotrexate) [Internet].

Bimekizumab (Bimzelx): CADTH Reimbursement Recommendation: Indication: For the treatment of adult patients with active psoriatic arthritis. Bimekizumab can be used alone or in combination with a conventional non-biologic disease-modifying antirheumatic drug (e.g., methotrexate) [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2024 Jun.

Table of Contents

7.
Belimumab (Benlysta): CADTH Reimbursement Recommendation: Indication: In addition to standard therapy for treatment of active lupus nephritis in adult patients [Internet].

Belimumab (Benlysta): CADTH Reimbursement Recommendation: Indication: In addition to standard therapy for treatment of active lupus nephritis in adult patients [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2023 Feb.

Table of Contents

8.
Deucravacitinib (Sotyktu): CADTH Reimbursement Recommendation: Indication: For the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy [Internet].

Deucravacitinib (Sotyktu): CADTH Reimbursement Recommendation: Indication: For the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2023 Aug.

Table of Contents

9.
Upadacitinib (Rinvoq): CADTH Reimbursement Recommendation: Indication: For the treatment of adults with active ankylosing spondylitis who have had an inadequate response to a biologic disease-modifying antirheumatic drug or when use of those therapies is inadvisable. Upadacitinib may be used as monotherapy or in combination with nonsteroidal anti-inflammatory drugs [Internet].

Upadacitinib (Rinvoq): CADTH Reimbursement Recommendation: Indication: For the treatment of adults with active ankylosing spondylitis who have had an inadequate response to a biologic disease-modifying antirheumatic drug or when use of those therapies is inadvisable. Upadacitinib may be used as monotherapy or in combination with nonsteroidal anti-inflammatory drugs [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2023 May.

Table of Contents

10.
CADTH Canadian Drug Expert Committee Recommendation: Risankizumab (Skyrizi — Abbvie): Indication: Adult patients with moderate to severe plaque psoriasis [Internet].

CADTH Canadian Drug Expert Committee Recommendation: Risankizumab (Skyrizi — Abbvie): Indication: Adult patients with moderate to severe plaque psoriasis [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 May.

Table of Contents

11.
Management of Type 2 Diabetes Mellitus [Internet].

Management of Type 2 Diabetes Mellitus [Internet].

Richardson CR, Borgeson JR, Van Harrison R, et al.

Ann Arbor (MI): Michigan Medicine University of Michigan; 2021 Oct.

Table of Contents

12.
Psoriasis: assessment and management.

Psoriasis: assessment and management.

London: National Institute for Health and Care Excellence (NICE); 2017 Sep 1. (NICE Clinical Guidelines, No. 153.)

Table of Contents

13.
CADTH Canadian Drug Expert Committee Recommendation: Baricitinib (Olumiant — Eli Lilly Canada Inc.): Indication: For use in combination with methotrexate (MTX) for the treatment of adult patients with moderate to severe rheumatoid arthritis (RA) who have responded inadequately to one or more disease-modifying anti-rheumatic drugs (DMARDs). Baricitinib may also be used as monotherapy in cases of intolerance to MTX [Internet].

CADTH Canadian Drug Expert Committee Recommendation: Baricitinib (Olumiant — Eli Lilly Canada Inc.): Indication: For use in combination with methotrexate (MTX) for the treatment of adult patients with moderate to severe rheumatoid arthritis (RA) who have responded inadequately to one or more disease-modifying anti-rheumatic drugs (DMARDs). Baricitinib may also be used as monotherapy in cases of intolerance to MTX [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 Aug.

Table of Contents

14.
CADTH Canadian Drug Expert Committee Recommendation: Ixekizumab (Taltz — Eli Lilly Canada Inc.): Indication: Adult patients with active psoriatic arthritis (PsA) who have responded inadequately to, or are intolerant to one or more disease-modifying antirheumatic drugs (DMARD) [Internet].

CADTH Canadian Drug Expert Committee Recommendation: Ixekizumab (Taltz — Eli Lilly Canada Inc.): Indication: Adult patients with active psoriatic arthritis (PsA) who have responded inadequately to, or are intolerant to one or more disease-modifying antirheumatic drugs (DMARD) [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Aug.

Table of Contents

15.
Belumosudil (Rezurock): CADTH Reimbursement Recommendation: Indication: For the treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease after failure of at least 2 prior lines of systemic therapy [Internet].

Belumosudil (Rezurock): CADTH Reimbursement Recommendation: Indication: For the treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease after failure of at least 2 prior lines of systemic therapy [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2024 Mar.

Table of Contents

16.
CADTH Canadian Drug Expert Committee Final Recommendation Sarilumab: (Kevzara — Sanofi Genzyme): Indication: Rheumatoid Arthritis [Internet].

CADTH Canadian Drug Expert Committee Final Recommendation Sarilumab: (Kevzara — Sanofi Genzyme): Indication: Rheumatoid Arthritis [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Apr 18.

Table of Contents

17.
CADTH Canadian Drug Expert Committee Recommendation: Guselkumab (Tremfya — Janssen Inc.): Indication: For the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy [Internet].

CADTH Canadian Drug Expert Committee Recommendation: Guselkumab (Tremfya — Janssen Inc.): Indication: For the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Feb.

Table of Contents

18.
CADTH Canadian Drug Expert Committee Final Recommendation: Ixekizumab: (Taltz — Eli Lilly Canada Inc.): Indication: Moderate to Severe Plaque Psoriasis [Internet].

CADTH Canadian Drug Expert Committee Final Recommendation: Ixekizumab: (Taltz — Eli Lilly Canada Inc.): Indication: Moderate to Severe Plaque Psoriasis [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2016 Oct 25.

Table of Contents

19.
Spondyloarthritis in over 16s: diagnosis and management.

Spondyloarthritis in over 16s: diagnosis and management.

London: National Institute for Health and Care Excellence (NICE); 2017 Jun. (NICE Guideline, No. 65.)

Table of Contents

20.
Ruxolitinib (Jakavi): CADTH Reimbursement Recommendation: Indication: For the treatment of chronic graft-versus-host disease in adults and pediatric patients aged 12 years and older who have inadequate response to corticosteroids or other systemic therapies [Internet].

Ruxolitinib (Jakavi): CADTH Reimbursement Recommendation: Indication: For the treatment of chronic graft-versus-host disease in adults and pediatric patients aged 12 years and older who have inadequate response to corticosteroids or other systemic therapies [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Jul.

Table of Contents

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Search details

See more...

Recent activity

Clear Turn Off Turn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...